Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.

Wei, Huiqiang; Duan, Yuqing; Gou, Wenfeng; Cui, Jie; Ning, Hongxin; Li, Deguan; Qin, Yong; Liu, Qiang; Li, Yiliang

Wei, Huiqiang; Duan, Yuqing; Gou, Wenfeng; Cui, Jie; Ning, Hongxin; Li, Deguan; Qin, Yong; Liu, Qiang; Li, Yiliang.

Afiliação

Wei H; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.
Duan Y; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.
Gou W; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.
Cui J; Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Ning H; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.
Li D; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China.
Qin Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: yongqin@mdanderson.org.
Liu Q; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China. Electronic address: liuqiang@irm-cams.ac.cn.
Li Y; Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, 300192, China. Electronic address: liyiliang@irm-cams.ac.cn.

Eur J Med Chem ; 181: 111552, 2019 Nov 01.

Article em En | MEDLINE | ID: mdl-31387063

Assuntos

Compostos de Anilina/farmacologia; Antineoplásicos/farmacologia; Desenho de Fármacos; Inibidores de Proteínas Quinases/farmacologia; Quinazolinas/farmacologia; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores; Compostos de Anilina/síntese química; Compostos de Anilina/química; Antineoplásicos/síntese química; Antineoplásicos/química; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Relação Dose-Resposta a Droga; Ensaios de Seleção de Medicamentos Antitumorais; Receptores ErbB/antagonistas & inibidores; Receptores ErbB/metabolismo; Humanos; Hipóxia/tratamento farmacológico; Hipóxia/metabolismo; Simulação de Acoplamento Molecular; Estrutura Molecular; Inibidores de Proteínas Quinases/síntese química; Inibidores de Proteínas Quinases/química; Quinazolinas/síntese química; Quinazolinas/química; Relação Estrutura-Atividade; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo

Palavras-chave

3-Nitro-1,2,4-triazole; EGFR; Hypoxia; Tyrosine kinase inhibitor; VEGFR-2; Vandetanib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinazolinas / Desenho de Fármacos / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Inibidores de Proteínas Quinases / Compostos de Anilina / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: França

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google